Review Article| Volume 351, ISSUE 3, P309-316, March 2016

Download started.


Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease


      Blockers of the renin-angiotensin-aldosterone system (RAAS), such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are routinely used in patients with chronic kidney disease because of their cardiovascular (CV) and renoprotective effects. However, there are no uniform recommendations about RAAS blockers for CV protection in the end-stage renal disease (ESRD) population other than the preferred drug class for blood pressure control. This uncertainty stems from the fact that patients with ESRD were generally excluded from randomized controlled trials evaluating the cardioprotective benefits of RAAS blockers. It is important to weigh the potential harms associated with the use of RAAS blockers, such as electrolyte disturbances and worsening anemia, with their role in protection of residual kidney function, alleviation of thirst and potential CV benefits. The objective of this review is to summarize the current knowledge about the use of RAAS blockers in patients with ESRD.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • National Kidney Foundation
        K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
        Am J Kidney Dis. 2004; 43: S1-S290
        • Sica D.A.
        Pharmacotherapy in congestive heart failure: angiotensin II and thirst: therapeutic considerations.
        Congest Heart Fail. 2001; 7: 325-328
        • Brener Z.Z.
        • Kotanko P.
        • Thijssen S.
        • et al.
        Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians.
        Am J Med Sci. 2010; 339: 453-456
        • Wang A.Y.
        • Lai K.N.
        The importance of residual renal function in dialysis patients.
        Kidney Int. 2006; 69: 1726-1732
        • Jager K.J.
        • Merkus M.P.
        • Dekker F.W.
        • et al.
        Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group.
        Kidney Int. 1999; 55: 1476-1485
        • Bargman J.M.
        • Thorpe K.E.
        • Churchill D.N.
        Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.
        J Am Soc Nephrol. 2001; 12: 2158-2162
        • National Kidney Foundation
        K/DOQI clinical practice guidelines for peritoneal dialysis adequacy, 2000.
        Am J Kidney Dis. 2001; 37: S65-S136
        • Moist L.M.
        • Port F.K.
        • Orzol S.M.
        • et al.
        Predictors of loss of residual renal function among new dialysis patients.
        J Am Soc Nephrol. 2000; 11: 556-564
        • Xydakis D.
        • Papadogiannakis A.
        • Sfakianaki M.
        • et al.
        Residual renal function in hemodialysis patients: the role of angiotensin-converting enzyme inhibitor in its preservation.
        ISRN Nephrol. 2013; 2013: 184-527
        • Itoh Y.
        • Fujikawa T.
        • Toya Y.
        • et al.
        Effect of renin-angiotensin system inhibitor on residual glomerular filtration rate in hemodialysis patients.
        Ther Apher Dial. 2012; 16: 554-559
        • Reyes-Marin F.A.
        • Calzada C.
        • Ballesteros A.
        • et al.
        Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study.
        Rev Invest Clin. 2012; 64: 315-321
        • Li P.K.
        • Chow K.M.
        • Wong T.Y.
        • et al.
        Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.
        Ann Intern Med. 2003; 139: 105-112
        • Kjaergaard K.D.
        • Peters C.D.
        • Jespersen B.
        • et al.
        Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
        Am J Kidney Dis. 2014; 64: 892-901
        • Ha I.S.
        • Yap H.K.
        • Munarriz R.L.
        • et al.
        Risk factors for loss of residual renal function in children treated with chronic peritoneal dialysis.
        Kidney Int. 2015; 88: 605-613
        • Taal M.W.
        • Brenner B.M.
        Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
        Kidney Int. 2000; 57: 1803-1817
        • Saran R.
        • Bragg-Gresham J.L.
        • Rayner H.C.
        • et al.
        Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS.
        Kidney Int. 2003; 64: 254-262
        • Lee M.J.
        • Doh F.M.
        • Kim C.H.
        • et al.
        Interdialytic weight gain and cardiovascular outcome in incident hemodialysis patients.
        Am J Nephrol. 2014; 39: 427-435
        • Johnson A.K.
        • Mann J.F.
        • Rascher W.
        • et al.
        Plasma angiotensin II concentrations and experimentally induced thirst.
        Am J Physiol. 1981; 240: R229-R234
        • Graziani G.
        • Badalamenti S.
        • Del Bo A.
        • et al.
        Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment.
        Kidney Int. 1993; 44: 107-114
        • Yamamoto T.
        • Shimizu M.
        • Morioka M.
        • et al.
        Role of angiotensin II in the pathogenesis of hyperdipsia in chronic renal failure.
        J Am Med Assoc. 1986; 256: 604-608
        • Oldenburg B.
        • MacDonald G.J.
        • Shelley S.
        Controlled trial of enalapril in patients with chronic fluid overload undergoing dialysis.
        Br Med J (Clin Res Ed). 1988; 296: 1089-1091
        • Bastani B.
        • Redington J.
        Lack of efficacy of angiotensin-converting enzyme inhibitors in reducing interdialytic weight gain.
        Am J Kidney Dis. 1994; 24: 907-911
        • Heitzmann D.
        • Warth R.
        Physiology and pathophysiology of potassium channels in gastrointestinal epithelia.
        Physiol Rev. 2008; 88: 1119-1182
        • Fang W.
        • Oreopoulos D.G.
        • Bargman J.M.
        Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.
        Nephrol Dial Transplant. 2008; 23: 3704-3710
        • Tzamaloukas A.H.
        • Avasthi P.S.
        Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis.
        Am J Nephrol. 1987; 7: 101-109
        • Sacchetti A.
        • Stuccio N.
        • Panebianco P.
        • et al.
        ED hemodialysis for treatment of renal failure emergencies.
        Am J Emerg Med. 1999; 17: 305-307
        • Garthwaite E.
        • Bhandari S.
        The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
        Artif Organs. 2009; 33: 641-647
        • Lin H.H.
        • Yang Y.F.
        • Chang J.K.
        • et al.
        Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients.
        Ren Fail. 2009; 31: 942-945
        • Krajina-Andricevic M.
        • Zibar L.
        • Juras K.
        • et al.
        Ramipril and risk of hyperkalemia in chronic hemodialysis patients.
        Coll Antropol. 2011; 35: 537-542
        • Zhang Q.
        • Luan H.
        • Wang L.
        • et al.
        Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis.
        J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 785-792
        • Martin R.S.
        • Panese S.
        • Virginillo M.
        • et al.
        Increased secretion of potassium in the rectum of humans with chronic renal failure.
        Am J Kidney Dis. 1986; 8: 105-110
        • Hatch M.
        • Freel R.W.
        • Vaziri N.D.
        Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure.
        Am J Physiol. 1998; 274: F275-F282
        • Agarwal R.
        • Afzalpurkar R.
        • Fordtran J.S.
        Pathophysiology of potassium absorption and secretion by the human intestine.
        Gastroenterology. 1994; 107: 548-571
        • Gross E.
        • Rothstein M.
        • Dombek S.
        • et al.
        Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
        Am J Kidney Dis. 2005; 46: 94-101
        • Putcha N.
        • Allon M.
        Management of hyperkalemia in dialysis patients.
        Semin Dial. 2007; 20: 431-439
        • Weir M.R.
        • Bakris G.L.
        • Bushinsky D.A.
        • et al.
        Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
        N Engl J Med. 2015; 372: 211-221
        • Packham D.K.
        • Rasmussen H.S.
        • Lavin P.T.
        • et al.
        Sodium zirconium cyclosilicate in hyperkalemia.
        N Engl J Med. 2015; 372: 222-231
        • Segal G.M.
        • Eschbach J.W.
        • Egrie J.C.
        • et al.
        The anemia of end-stage renal disease: hematopoietic progenitor cell response.
        Kidney Int. 1988; 33: 983-988
        • Albitar S.
        • Genin R.
        • Fen-Chong M.
        • et al.
        High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
        Nephrol Dial Transplant. 1998; 13: 1206-1210
        • Macdougall I.C.
        The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.
        Nephrol Dial Transplant. 1999; 14: 1836-1841
        • Danovitch G.M.
        • Jamgotchian N.J.
        • Eggena P.H.
        • et al.
        Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism.
        Transplantation. 1995; 60: 132-137
        • Walter J.
        Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients?.
        Nephrol Dial Transplant. 1993; 8: 1428
        • Qureshi I.Z.
        • Abid K.
        • Ambreen F.
        • et al.
        Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
        Saudi Med J. 2007; 28: 193-196
        • Hayashi K.
        • Hasegawa K.
        • Kobayashi S.
        Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin.
        Kidney Int. 2001; 60: 1910-1916
        • Azizi M.
        • Rousseau A.
        • Ezan E.
        • et al.
        Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
        J Clin Invest. 1996; 97: 839-844
        • Ishani A.
        • Weinhandl E.
        • Zhao Z.
        • et al.
        Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
        J Am Coll Cardiol. 2005; 45: 391-399
        • Mrug M.
        • Stopka T.
        • Julian B.A.
        • et al.
        Angiotensin II stimulates proliferation of normal early erythroid progenitors.
        J Clin Invest. 1997; 100: 2310-2314
        • Efrati S.
        • Zaidenstein R.
        • Dishy V.
        • et al.
        ACE inhibitors and survival of hemodialysis patients.
        Am J Kidney Dis. 2002; 40: 1023-1029
        • Takahashi A.
        • Takase H.
        • Toriyama T.
        • et al.
        Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study.
        Nephrol Dial Transplant. 2006; 21: 2507-2512
        • Bajaj R.R.
        • Wald R.
        • Hackam D.G.
        • et al.
        Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study.
        Arch Intern Med. 2012; 172: 591-593
        • Chang T.I.
        • Shilane D.
        • Brunelli S.M.
        • et al.
        Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis.
        Am Heart J. 2011; 162: 324-330
        • Zannad F.
        • Kessler M.
        • Lehert P.
        • et al.
        Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.
        Kidney Int. 2006; 70: 1318-1324
        • Chan K.E.
        • Ikizler T.A.
        • Gamboa J.L.
        • et al.
        Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.
        Kidney Int. 2011; 80: 978-985
        • Cannella G.
        • Paoletti E.
        • Delfino R.
        • et al.
        Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects.
        Am J Kidney Dis. 1997; 30: 659-664
        • Klingbeil A.U.
        • Schneider M.
        • Martus P.
        • et al.
        A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.
        Am J Med. 2003; 115: 41-46
        • Dahlof B.
        • Devereux R.B.
        • Kjeldsen S.E.
        • et al.
        Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
        Lancet. 2002; 359: 995-1003
        • Ruggenenti P.
        • Iliev I.
        • Costa G.M.
        • et al.
        Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).
        Diabetes Care. 2008; 31: 1629-1634
        • Paoletti E.
        • Cassottana P.
        • Bellino D.
        • et al.
        Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors.
        Am J Kidney Dis. 2002; 40: 728-736
        • Devereux R.B.
        • Wachtell K.
        • Gerdts E.
        • et al.
        Prognostic significance of left ventricular mass change during treatment of hypertension.
        J Am Med Assoc. 2004; 292: 2350-2356
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • et al.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
        N Engl J Med. 2000; 342: 145-153
        • Mathew J.
        • Sleight P.
        • Lonn E.
        • et al.
        Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
        Circulation. 2001; 104: 1615-1621
        • Flather M.D.
        • Yusuf S.
        • Kober L.
        • et al.
        Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.
        Lancet. 2000; 355: 1575-1581
        • Tai D.J.
        • Lim T.W.
        • James M.T.
        • et al.
        Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis.
        Clin J Am Soc Nephrol. 2010; 5: 623-630
        • Yang L.Y.
        • Ge X.
        • Wang Y.L.
        • et al.
        Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis.
        Am J Med Sci. 2013; 345: 1-9
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
        Circulation. 2013; 128: e240-e327
        • Cice G.
        • Di Benedetto A.
        • D׳Isa S.
        • et al.
        Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
        J Am Coll Cardiol. 2010; 56: 1701-1708
        • Tang C.H.
        • Chen T.H.
        • Wang C.C.
        • et al.
        Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.
        Eur J Heart Fail. 2013; 15: 1194-1202
        • Toto R.D.
        Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
        Curr Hypertens Rep. 2006; 8: 409-412
        • Ram C.V.
        • Fenves A.Z.
        Management of hypertension in hemodialysis patients.
        Curr Hypertens Rep. 2009; 11: 292-298
        • Luik A.J.
        • Kooman J.P.
        • Leunissen K.M.
        Hypertension in haemodialysis patients: is it only hypervolaemia?.
        Nephrol Dial Transplant. 1997; 12: 1557-1560
        • Kooman J.P.
        • Gladziwa U.
        • Bocker G.
        • et al.
        Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values.
        Nephrol Dial Transplant. 1992; 7: 917-923
        • Agarwal R.
        • Nissenson A.R.
        • Batlle D.
        • et al.
        Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.
        Am J Med. 2003; 115: 291-297
        • Horl M.P.
        • Tepel M.
        Drug therapy for hypertension in hemodialysis patients.
        Minerva Med. 2005; 96: 277-285
        • Agarwal R.
        • Sinha A.D.
        • Pappas M.K.
        • et al.
        Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial.
        Nephrol Dial Transplant. 2014; 29: 672-681
        • Davenport A.
        • Cox C.
        • Thuraisingham R.
        Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension.
        Kidney Int. 2008; 73: 759-764